Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement

Michael J. Peluso, 1, 2, 3, 4 J. Daniel Kelly, 2, 3, 4 Scott Lu, 1 Sarah A. Goldberg, 4 Michelle C. Davidson, 2 Sujata Mathur, 5 Matthew S. Durstenfeld, 5 Matthew A. Spinelli, 1 Rebecca Hoh, 1 Viva Tai, 1 Emily A. Fehrman, 1 Leonel Torres, 15 Yanel Hernandez, 1 Meghann C. Williams, 1 Mireya I. Arreguin, 1 Lynn H. Ngo, 1 Monika Deswal, 1 Sadie E. Munter, 16 Enrique O. Martinez, 12 Khamal A. Anglin, 2 Mariela D. Romero, 1 Jacqueline Tays, 2 Paulina R. Rugart, 2 Jessica Y. Chen, 24 Hannah M. Sans, 2 Victoria W. Murray, 1 Payton K. Ellis, 3 Kevin C. Donohue, 2 Jonathan A. Massachi, 2 Jacob O. Weiss, 2 Irum Mehdi, 2 Jesus Pineda-Ramirez, 2 Alex F. Tang, 1 Megan A. Wenger, 3 Melissa T. Assenzo, 3 Yan Yuan, 2 Melissa R. Krone, 3 Rachel L. Rutishauser, 2 Isabel Rodriguez-Barraquer, 2 Bryan Greenhouse, 1 John A. Sauceda, 1 Monica Gandhi, 1, 6 Aaron Wolfe Scheffler, 6 Priscilla Y. Hsieh, 3 Timothy J. Henrich, 5 Steven G. Deeks, 1 and Jeffrey N. Martin 2

1 Division of Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA; 2 Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA; 3 Institute of Global Health Sciences, University of California, San Francisco, San Francisco, California, USA; 4 F. I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA; 5 Division of Cardiology, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA; 6 Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA; and 7 Center for AIDS Prevention Studies, University of California, San Francisco, San Francisco, California, USA

Background. There is mounting evidence for the presence of postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC), but there is limited information on the spectrum, magnitude, duration, and patterns of these sequelae as well as their influence on quality of life.

Methods. We assembled a cohort of adults with a documented history of SARS-CoV-2 RNA positivity at ≥2 weeks past onset of coronavirus disease 2019 (COVID-19) symptoms or, if asymptomatic, first positive test. At 4-month intervals, we queried physical and mental health symptoms and quality of life.

Results. Of the first 179 participants enrolled, 10 were asymptomatic during the acute phase of SARS-CoV-2 infection, 125 were symptomatic but not hospitalized, and 44 were symptomatic and hospitalized. During the postacute phase, fatigue, shortness of breath, concentration problems, headaches, trouble sleeping, and anosmia/dysgeusia were most common through 8 months of observation. Symptoms were typically at least somewhat bothersome and sometimes exhibited a waxing-and-waning course. Some participants experienced symptoms of depression, anxiety, and post-traumatic stress, as well as difficulties with performance of usual activities. The median visual analogue scale rating of general health was lower at 4 and 8 months compared with pre-COVID-19. Two clusters of symptom domains were identified.

Conclusions. Many participants report bothersome symptoms following onset of COVID-19 with variable patterns of persistence and impact on quality of life. The substantial variability suggests the existence of multiple subphenotypes of PASC. A rigorous approach to the prospective measurement of symptoms and functional manifestations sets the stage for the next phase of research focusing on the pathophysiological causes of the various subgroups of PASC.

Keywords. COVID-19; long COVID; post-acute sequelae of SARS-CoV-2 (PASC); quality of life; SARS-CoV-2.
were limited by studying populations who had not all been confirmed to have SARS-CoV-2 [9], were enriched with patients who were hospitalized and may thus be more indicative of the effects of hospitalization than COVID-19 [10, 11], or had short follow-up [12]. Furthermore, there is little systematic information on the magnitude or severity, longitudinal within-person persistence, or co-occurrence of PASC symptoms. As millions of individuals worldwide continue to become infected with SARS-CoV-2, the public health implications of PASC and the need to uncover interventions to prevent or treat it are self-evident.

To rapidly gain insights into PASC, we established a cohort dedicated to the study of PASC. We intentionally sought to enroll patients with RNA-confirmed SARS-CoV-2 infection recovering from a wide spectrum of acute disease manifestations. Herein, we describe the assembly of this cohort along with some key methodologic approaches to study design, measurement of self-reported aspects of PASC, and portrayal of findings that could inform this nascent field of research. As a demonstration of these approaches, we also describe our preliminary findings in cohort participants regarding the spectrum, magnitude, duration, and co-occurrence of physical and mental health symptoms, as well as their influence on quality of life through 8 months of observation following acute SARS-CoV-2 infection.

METHODS

Patient Consent
The institutional review board of the University of California, San Francisco, approved this study. All participants provided written informed consent.

Overall Design
We enrolled consecutive adults at ≥2 weeks past onset of COVID-19 symptoms or, if asymptomatic, first positive diagnostic test for SARS-CoV-2 and who responded to notification and advertisements regarding the study. Participants underwent comprehensive questionnaire-based evaluation and biological specimen collection at an initial visit and every 4 months thereafter.

Participants
Any individual age ≥18 years with documentation of SARS-CoV-2 RNA detected on a prior nucleic acid amplification test and ability to travel to our research site in San Francisco was eligible to participate. Minimal duration of time following symptom onset (or first positive RNA detection) depended on local infection control guidelines, starting with 28 days and subsequently shortening to 14 days. Participants were recruited through clinician referral, mailings to consecutive patients testing positive at University of California, San Francisco–affiliated testing sites, and response to medical center paper postings, websites, and advertisements. Although quotas were not set for distribution of acute SARS-CoV-2 disease manifestations, most recruitment resources were dedicated to attracting persons who had not been hospitalized, including asymptomatic individuals.

Processes
Once identified, participants deemed eligible by a phone interview were examined in person at the research center. Participants were administered structured questionnaires, asked to provide whole unstimulated saliva and/or a swab of gingival crevice fluid, and had peripheral blood collected, which was stored as serum, plasma, and cryopreserved peripheral blood mononuclear cells (PBMCs). Following the initial visit, participants were invited to complete additional visits every 4 months.

Measurements
A battery of instruments was assembled by a team of infectious disease clinicians and epidemiologists, aided by consultation with content specialists from pulmonology, cardiology, neurology, and mental health. Development of the instruments was an iterative process as information emerged regarding SARS-CoV-2 infection and recovery. These instruments queried about sociodemographic characteristics, medical history and concomitant medications, SARS-CoV-2 exposure, physical symptoms, quality of life, mental health, and substance use. With the exception of the mental health questions, which were self-administered, all questionnaires were interviewer-administered. Interviews were conducted in English or Spanish by bilingual research staff according to participant preference. Study instruments were available in both English and Spanish.

The Patient Health Questionnaire (PHQ) somatic symptom scale [13] was used to ascertain presence and magnitude of physical symptoms. Participants were specifically asked to describe symptoms only if they were new or worse compared with the period before COVID-19. In addition to this predetermined list of symptoms, participants were asked about any other symptoms they were experiencing. At the initial visit, participants were asked about symptoms experienced during the acute phase of their SARS-CoV-2 infection (the first 3 weeks after initial symptom onset) as well as the prior 2 days (ie, current moment). At all subsequent visits, participants were asked about any symptoms experienced since their last visit, with separate ascertainment regarding the prior 2 days (ie, current moment). Quality of life was measured using the EuroQol metrics [14], and mental health symptoms were measured using a combination of the General Anxiety Disorder–7 (GAD-7) [15], PHQ-8 [16], and an adaptive 4-item version of the Posttraumatic Stress Disorder (PTSD) Checklist (PCL) 5 [17–19]. In contrast to physical symptoms, questions about quality of life and mental health symptoms were not limited to new perceptions or feelings that occurred since onset of COVID-19; instead, they were answered from the perspective of the time of the interview, regardless of whether their presence predated the SARS-CoV-2 diagnosis.
Participants were described according to severity of COVID-19 during the first 21 days following onset of symptoms, which was classified as asymptomatic, symptomatic but not hospitalized, and hospitalized for the purposes of management of severe COVID-19. There were no hospitalizations solely for infection control or nonacute care. For each of the domains of physical symptoms, mental health symptoms, and quality of life, we characterized 4 time periods: (1) acute illness (0–3 weeks), (2) early recovery (centered at 6 weeks, range 3–10 weeks), (3) late recovery 1 (centered at 16 weeks, range 12–20 weeks), and (4) late recovery 2 (centered at 32 weeks, range 28–36 weeks).

To explore the extent to which patients cluster according to their symptoms, we implemented a model-based approach and focused on participants reporting at least 1 symptom present during the first late recovery period. To decrease multidimensionality, we first reduced 32 symptoms into 7 of domains of complaints (fatigue, upper respiratory, cardiopulmonary, gastrointestinal, musculoskeletal, neurological, or sleep), each containing between 1 and 8 symptoms. Participants were considered to possess the domain if they reported at least 1 symptom. The model-based approach attempted to cluster participants with similar patterns of symptom domains into k groups, where the number of groups and their associated distribution of domains are estimated via a modified expectation–maximization algorithm with model selection automatically performed via the Bayesian Information Criterion (BIC) [20]. Given the limited sample size, we performed a grid search between 2 and 6 clusters (k = 2, . . . , 6). For a given k clusters, participants were assigned to the estimated latent distribution most likely to generate their observed symptom domains. Cluster performance was evaluated using the average silhouette score, a measure quantifying the internal validity of estimated cluster assignments within and across a sample.

We used Stata (version 16.1; StataCorp, College Station, TX, USA) throughout, with the exception of R for the alluvial plots (alluvial) and clustering (VarSelLCM [21]).

RESULTS
Characteristics of Participants at Enrollment
From April 21, 2020, to January 4, 2021, we enrolled 179 adult participants; most (60%) were enrolled between April and July 2020. At the time of enrollment, participants were a median (interquartile range [IQR]) of 1.8 (1.2–2.7) days past the date of symptom onset/first positive RNA detection. The cohort represented the full spectrum of illness severity during the acute phase of SARS-CoV-2 infection (Table 1); 10 were asymptomatic, 125 were symptomatic but not hospitalized, and 44 were symptomatic and hospitalized. Among those who had been hospitalized, 37 (88%) required supplemental oxygen, but only 6 (14%) required mechanical ventilation. Few participants had received therapeutic interventions during acute SARS-CoV-2 infection; 6% received remdesivir, 10% glucocorticoids, and 2% convalescent plasma.

Follow-up of Cohort
Longitudinal observation was scheduled every 4 months following onset of symptoms/date of first detected SARS-CoV-2 RNA. At 4 months, of the 165 participants who were evaluable (ie, whose duration since symptom onset was at least 20.5 weeks, the outer boundary of the window for this visit), 143 (87%) completed the study visit. At 8 months, of the 111 participants who were evaluable (ie, whose duration since symptom onset was at least 36.5 weeks), 68 (61%) completed the study visit. Twenty-five individuals (23%) missed their 8-month visit but had a subsequent visit and thus were not lost to follow-up. Reasons for such visit delays included reduced availability during the winter holidays, re-implementation of local stay-at-home orders, reduced staffing density due to medical center guidelines before the SARS-CoV-2 vaccine rollout, and participant concerns related to the winter 2020 COVID-19 surge. Of the remaining 18 individuals (16% of the 111 who are theoretically evaluable), 13 have formally withdrawn from the study (no time because of family obligations related to dependent care [n = 3], inability to tolerate blood draws [n = 3], moved out of region [n = 2], and declined to provide a reason [n = 5]), 3 were withdrawn by study investigators because of behavioral issues, and 2 remain in contact with the study but have not decided whether they wish to resume. No participant is known to have died. No participants were vaccinated against SARS-CoV-2 during the study period.

Physical and Mental Health Symptoms
The most common physical symptoms during the acute phase of SARS-CoV-2 infection were fatigue, fever, myalgia, cough, and anosmia/dysgeusia (Figure 1). In the postacute phase, fatigue, shortness of breath, concentration problems, headaches, trouble sleeping, and anosmia/dysgeusia were the most commonly reported, but a variety of other symptoms were endorsed by at least some participants at each time point. Not all participants, however, complained of symptoms. At early recovery (3–10 weeks), 61 of 126 participants reported no current symptoms. At the late recovery time points, 54 of 143 reported no current symptoms at the first late follow-up time point (12–20 weeks), and 16 of 68 reported no symptoms at the second late follow-up time point (28–36 weeks). When symptoms were present, very few participants stated that the symptom did not bother them (Table 2). For some symptoms (eg, “trouble concentrating, trouble with thinking, or trouble with memory”), >50% of the participants in the 2 late recovery periods who endorsed the symptom reported that it bothered them “a lot.” Among the subset of participants with complete data at all 3 time periods (n = 38), there was substantial within-individual variation in the
Table 1. Characteristics at Time of SARS-CoV-2 Infection Among Participants Enrolled in a Study of Postacute Sequelae of SARS-CoV-2 Infection

| Characteristic                        | Asymptomatic (n = 10) | Symptomatic Not Hospitalized (n = 125) | Symptomatic Hospitalized (n = 44) | All (n = 179) |
|---------------------------------------|-----------------------|----------------------------------------|-----------------------------------|--------------|
| Age, y                                | 45.5 (38–55)          | 46 (46–57)                             | 49 (37–57)                        | 48 (37–57)  |
|                                       | (23–70)               | (19–76)                                | (19–85)                           | (19–85)     |
| Female birth sex                      | 2 (20)                | 61 (49)                                | 15 (34)                           | 79 (44)     |
| Gender identity                       |                       |                                        |                                   |              |
| Female                                | 2 (20)                | 62 (49)                                | 15 (34)                           | 79 (44)     |
| Male                                  | 8 (80)                | 61 (49)                                | 28 (64)                           | 98 (55)     |
| Transgender male                      | 0 (0)                 | 1 (0.8)                                | 1 (2)                             | 2 (1.0)     |
| Transgender female                    | 0 (0)                 | 0 (0)                                  | 0 (0)                             | 0 (0)       |
| Prefer not to answer                  | 0 (0)                 | 1 (0.8)                                | 0 (0)                             | 1 (0.5)     |
| Race/ethnicity                        |                       |                                        |                                   |              |
| Hispanic/Latino                       | 3 (30)                | 29 (24)                                | 24 (55)                           | 56 (32)     |
| Hawaiian/Pacific Islander             | 0 (0)                 | 2 (1.7)                                | 2 (4.6)                           | 4 (2.3)     |
| White                                 | 5 (50)                | 75 (62)                                | 9 (20)                            | 89 (51)     |
| Black/African American                | 1 (10)                | 6 (5.0)                                | 2 (4.6)                           | 9 (5.1)     |
| Asian                                 | 1 (10)                | 9 (7.4)                                | 7 (16)                            | 17 (9.7)    |
| Native American/Alaska Native         | 0 (0)                 | 0 (0)                                  | 0 (0)                             | 0 (0)       |
| Education                             |                       |                                        |                                   |              |
| Any HS or less                        | 1 (10)                | 16 (13)                                | 26 (59)                           | 43 (24)     |
| Any college                           | 5 (50)                | 53 (42)                                | 12 (27)                           | 70 (39)     |
| Any graduate school                   | 4 (40)                | 56 (45)                                | 6 (14)                            | 66 (37)     |
| Sexual orientation                    |                       |                                        |                                   |              |
| Asexual                               | 0 (0)                 | 0 (0)                                  | 1 (4.2)                           | 1 (1.0)     |
| Bisexual                              | 0 (0)                 | 2 (1.9)                                | 0 (0)                             | 2 (1.5)     |
| Gay/lesbian                           | 3 (33)                | 28 (27)                                | 4 (17)                            | 35 (25)     |
| Straight/heterosexual                 | 5 (56)                | 71 (68)                                | 19 (79)                           | 95 (69)     |
| Other                                 | 1 (11)                | 3 (2.9)                                | 0 (0)                             | 4 (2.9)     |
| Annual household income               |                       |                                        |                                   |              |
| ≤$50 000                              | 4 (40)                | 25 (23)                                | 16 (52)                           | 45 (30)     |
| $50 001–$100 000                      | 1 (10)                | 15 (14)                                | 7 (23)                            | 23 (15)     |
| $100 001–$300 000                     | 4 (40)                | 36 (33)                                | 6 (19)                            | 46 (31)     |
| >$300 000                             | 1 (10)                | 32 (30)                                | 2 (6.5)                           | 35 (23)     |
| Body mass index, kg/m²                |                       |                                        |                                   |              |
| ≤24.9                                 | 3 (30)                | 49 (39)                                | 4 (9.1)                           | 56 (31)     |
| 25–29.9                               | 3 (30)                | 35 (28)                                | 17 (39)                           | 55 (31)     |
| ≥30                                   | 4 (40)                | 41 (33)                                | 23 (52)                           | 68 (38)     |
| Self-reported comorbid conditions     |                       |                                        |                                   |              |
| Autoimmune                            | 2 (20)                | 3 (2.4)                                | 6 (14)                            | 11 (6.2)    |
| Cancer                                | 2 (20)                | 4 (3.2)                                | 1 (2.3)                           | 3 (7.9)     |
| Diabetes                              | 0 (0)                 | 7 (5.7)                                | 14 (32)                           | 21 (12)     |
| HIV                                   | 4 (40)                | 25 (20)                                | 3 (70)                            | 32 (18)     |
| Heart attack or heart failure         | 1 (10)                | 2 (1.6)                                | 1 (2.3)                           | 4 (2.2)     |
| Hypertension                          | 3 (30)                | 19 (15)                                | 15 (32)                           | 36 (20)     |
| Lung problems                         | 0 (0)                 | 17 (14)                                | 11 (25)                           | 28 (16)     |
| Kidney disease                        | 0 (0)                 | 1 (0.8)                                | 1 (2.3)                           | 2 (1.1)     |
| Ever used tobacco                     | 5 (50)                | 36 (29)                                | 13 (30)                           | 54 (30)     |

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

*Median interquartile range.

*Absolute range.

*Missing and nonresponse. Race/ethnicity: 3 missing, 1 prefer not to answer; sexual orientation: 41 missing, 1 prefer not to answer; income: 1 missing, 29 prefer not to answer; BMI: 6 missing; cancer: 1 missing; diabetes: 3 missing; HIV: 1 missing; hypertension: 1 missing; lung problems: 1 missing.

*Cancer requiring treatment within the 2 years before COVID-19.

*Asthma, COPD, emphysema, or bronchitis experienced in the 5 years before COVID-19.

*Cigarettes, cigars, or any product containing tobacco in a hookah.
presence of many symptoms over the study period (Figure 2). While most participants reported consistency in the presence or absence of each symptom over time, some participants reported the resolution of previously present symptoms, some reported the onset of previously absent symptoms, and some reported variability in the presence of symptoms.

Regarding mental health, some participants experienced symptoms of depression, anxiety, and post-traumatic stress during the late recovery phase (Table 3). Most of these symptoms were described as minimal or mild, but a small number of individuals experienced moderate or severe symptoms.

### Clustering of Symptoms

Among 82 participants experiencing at least 1 physical symptom in the late recovery period, model-based clustering identified 2 groups of participants (Cluster 1 = 40 participants and Cluster 2 = 42 participants) in whom presence of symptoms within group members was more similar to each other than to those in the other group. The clusters are characterized by the proportion of participants experiencing each of the 7 domains of symptoms (Table 4). Silhouette scores suggest that the cluster configuration for the first cluster is strong while the second cluster is poorly configured. Participants in Cluster 1 have higher prevalence of all symptom domains except for respiratory, indicating that symptom presence across the 7 domains is, in general, positively correlated. Cluster 1 is particularly distinguished from Cluster 2 in its greater absolute difference in prevalence of fatigue, cardiopulmonary symptoms, and gastrointestinal symptoms.

### Quality of Life

Measures of quality of life, which integrate across physical and mental health symptoms to depict functional impairments, showed expected high frequencies of inability to ambulate, perform self-care, and perform usual activities during the worst point of acute SARS-CoV-2 infection (Table 5). These frequencies were substantially higher than what participants reported before COVID-19. During the 2 late recovery periods, very few participants expressed moderate or more severe problems in self-care, but some reported difficulties with ambulation and performance of usual activities. Participant-rated health on a visual analogue scale of 0 to 100 was, again,
| Characteristic                      | Week 6, No. (%) | Week 16, No. (%) | Week 32, No. (%) |
|------------------------------------|----------------|-----------------|-----------------|
| Feeling tired or having low energy |                |                 |                 |
| Not bothered at all                | 1 (5.0)        | 1 (5.0)         | 1 (3.3)         |
| Bothered a little                  | 7 (35)         | 6 (30)          | 16 (53)         |
| Bothered a lot                      | 12 (60)        | 13 (65)         | 13 (43)         |
| Cough                              |                |                 |                 |
| Not bothered at all                | 1 (17)         | 2 (29)          | 2 (18)          |
| Bothered a little                  | 1 (17)         | 3 (43)          | 6 (55)          |
| Bothered a lot                      | 4 (67)         | 2 (29)          | 3 (27)          |
| Shortness of breath                |                |                 |                 |
| Not bothered at all                | 1 (8.3)        | 0 (0)           | 0 (0)           |
| Bothered a little                  | 4 (33)         | 7 (44)          | 8 (62)          |
| Bothered a lot                      | 7 (58)         | 9 (56)          | 5 (38)          |
| Chest pain                         |                |                 |                 |
| Not bothered at all                | 0 (0)          | 2 (14)          | 2 (20)          |
| Bothered a little                  | 3 (38)         | 5 (36)          | 4 (40)          |
| Bothered a lot                      | 5 (63)         | 7 (50)          | 4 (40)          |
| Feeling heart pound or race        |                |                 |                 |
| Not bothered at all                | 0 (0)          | 3 (25)          | 1 (9.1)         |
| Bothered a little                  | 4 (57)         | 6 (50)          | 5 (45)          |
| Bothered a lot                      | 3 (43)         | 3 (25)          | 5 (45)          |
| Runny nose or congestion           |                |                 |                 |
| Not bothered at all                | -              | 2 (25)          | 1 (10)          |
| Bothered a little                  | -              | 3 (38)          | 6 (60)          |
| Bothered a lot                      | -              | 3 (38)          | 3 (30)          |
| Muscle aches                       |                |                 |                 |
| Not bothered at all                | 0 (0)          | 0 (0)           | 0 (0)           |
| Bothered a little                  | 2 (25)         | 5 (71)          | 5 (42)          |
| Bothered a lot                      | 6 (75)         | 2 (29)          | 7 (58)          |
| Loss of appetite                   |                |                 |                 |
| Not bothered at all                | -              | 7 (78)          | -               |
| Bothered a little                  | -              | 2 (22)          | -               |
| Bothered a lot                      | -              | 0 (0)           | -               |
| Nausea, gas, indigestion           |                |                 |                 |
| Not bothered at all                | -              | 2 (25)          | 2 (13)          |
| Bothered a little                  | -              | 3 (38)          | 6 (40)          |
| Bothered a lot                      | -              | 3 (38)          | 7 (47)          |
| Stomach pain                       |                |                 |                 |
| Not bothered at all                | -              | -               | 0 (0)           |
| Bothered a little                  | -              | -               | 2 (29)          |
| Bothered a lot                      | -              | -               | 5 (71)          |
| Constipation                        |                |                 |                 |
| Not bothered at all                | -              | -               | 3 (38)          |
| Bothered a little                  | -              | -               | 3 (38)          |
| Bothered a lot                      | -              | -               | 2 (25)          |
| Diarrhea or loose bowels           |                |                 |                 |
| Not bothered at all                | -              | 1 (17)          | 3 (25)          |
| Bothered a little                  | -              | 2 (33)          | 8 (67)          |
| Bothered a lot                      | -              | 3 (50)          | 1 (8.3)         |
| New spots or rash on skin          |                |                 |                 |
| Not bothered at all                | -              | 3 (43)          | 3 (25)          |
| Bothered a little                  | -              | 0 (0)           | 1 (8.3)         |
| Bothered a lot                      | -              | 4 (57)          | 8 (67)          |
| Trouble with smell or taste        |                |                 |                 |
| Not bothered at all                | 2 (25)         | 5 (50)          | 5 (29)          |
| Bothered a little                  | 2 (25)         | 3 (30)          | 4 (24)          |
| Bothered a lot                      | 4 (50)         | 2 (20)          | 8 (47)          |
much lower during the worst point of acute infection compared with before COVID-19 (Table 5). In the 2 late recovery periods, the median visual analogue scale value was lower than before COVID-19.

DISCUSSION

Within 2 months of the first documented case of community transmission of SARS-CoV-2 in the United States, we initiated a research cohort dedicated to studying the long-term impact of the infection. Overcoming some of the limitations of earlier work, we limited our population to participants with RNA-confirmed SARS-CoV-2 infection, included a large fraction of participants who had not been hospitalized, and extended observation to 8 months post–COVID-19 onset. We found that in the postacute phase of infection, there is a large spectrum of symptoms, ranging from generalized complaints such as fatigue to organ system–specific manifestations such as cardiopulmonary and neurocognitive symptoms to mental health symptoms of anxiety and depression. While few participants endorsed major alterations in quality of life, some individuals have not resumed normal function. Our data support emerging clinical anecdotes regarding the severity of symptoms.

Table 2. Continued

| Characteristic | Week 6, No. (%) | Week 16, No. (%) | Week 32, No. (%) |
|---------------|----------------|----------------|-----------------|
| Smelling an odor that is not actually there |               |                |                 |
| Not bothered at all | -             | -             | 4 (36)          |
| Bothered a little | -             | -             | 3 (27)          |
| Bothered a lot   | -             | -             | 4 (36)          |
| Trouble concentrating, trouble with thinking, or trouble with memory |               |                |                 |
| Not bothered at all | 1 (71)       | 1 (4)         | 0 (0)           |
| Bothered a little | 7 (50)        | 10 (40)       | 9 (35)          |
| Bothered a lot   | 6 (43)        | 14 (56)       | 17 (65)         |
| Headache        |               |                |                 |
| Not bothered at all | 0 (0)        | 8 (47)        | 0 (0)           |
| Bothered a little | 4 (40)        | 8 (47)        | 4 (27)          |
| Bothered a lot   | 6 (60)        | 1 (5.9)       | 11 (73)         |
| Trouble with vision, for example double vision, blurry vision, or other visual issues |               |                |                 |
| Not bothered at all | -             | 0 (0)        | 1 (9.1)         |
| Bothered a little | -             | 4 (33)        | 1 (9.1)         |
| Bothered a lot   | -             | 8 (67)        | 9 (82)          |
| Dizziness       |               |                |                 |
| Not bothered at all | -             | 0 (0)        | 1 (9.1)         |
| Bothered a little | -             | 4 (33)        | 1 (9.1)         |
| Bothered a lot   | -             | 8 (67)        | 9 (82)          |
| Trouble with balance or feeling unsteady |               |                |                 |
| Not bothered at all | 0 (0)        | 1 (9.1)       | 0 (0)           |
| Bothered a little | 4 (67)        | 6 (55)        | 4 (36)          |
| Bothered a lot   | 2 (33)        | 4 (36)        | 7 (64)          |
| Numbness, tingling, or pins and needles in arms or legs |               |                |                 |
| Not bothered at all | -             | 1 (10)        | 0 (0)           |
| Bothered a little | -             | 7 (70)        | 3 (23)          |
| Bothered a lot   | -             | 2 (20)        | 10 (76)         |
| Pain in arms, legs, or joints such as knees and hips |               |                |                 |
| Not bothered at all | -             | 0 (0)        | 0 (0)           |
| Bothered a little | -             | 1 (17)        | 6 (38)          |
| Bothered a lot   | -             | 5 (83)        | 10 (63)         |
| Back pain        |               |                |                 |
| Not bothered at all | -             | -             | 1 (11)          |
| Bothered a little | -             | -             | 3 (33)          |
| Bothered a lot   | -             | -             | 5 (56)          |
| Trouble sleeping |               |                |                 |
| Not bothered at all | 1 (11)       | 3 (19)        | 1 (5.6)         |
| Bothered a little | 2 (22)        | 3 (19)        | 7 (39)          |
| Bothered a lot   | 6 (66)        | 10 (63)       | 10 (56)         |

Abbreviation: COVID-19, coronavirus disease 2019.

*Responses to “When the symptom was at its worst, how much did it/does it bother you? Would you say you were not bothered at all, bothered a little, or bothered a lot?” Note: the total number of individuals experiencing each symptom at the time point can be calculated by adding the numbers of each response for the symptom at that time point.*
and their variability over time by providing evidence that these symptoms are of significant magnitude for many individuals, are not uniformly improving or worsening, and may cluster into distinct phenotypes. We believe that our approach to the self-reported aspects of phenotypic characterization of individuals with PASC will be critical to designing studies regarding the underlying pathogenesis of this complex condition.

Requiring an RNA-positive confirmed SARS-CoV-2 diagnosis for participation in PASC research is controversial. At certain times and places, access to testing has been limited and has disproportionately affected certain populations. Thus, excluding persons without a documented diagnosis could result in nonrepresentative study samples. On the other hand, recent work found that persistent physical symptoms were more commonly reported by persons with self-reported SARS-CoV-2 infection than those with objectively confirmed infection [22], suggesting that self-report may be misclassified. We contend that requiring a documented diagnosis depends upon the research objective. For research aimed at unraveling etiopathogenesis, like our study, we believe that specificity in eligibility criteria is paramount in order to optimize validity in the ultimate inferences. In treatment studies, more flexibility is encouraged, especially to give affected populations access to experimental therapy. In any case, any study enrolling both persons with and without documented SARS-CoV-2 infection should report findings stratified by diagnosis documentation status.

Several aspects of our symptom measurement provide greater context regarding their meaning, relevance, and utility. Throughout our interviews, we focus participants on limiting report of symptoms to those that started (or worsened) since COVID-19 onset. Interviewer-administered questionnaires allow us to achieve this emphasis. By limiting to symptoms starting (or worsening) after COVID-19 onset, we subtract the non-0 prevalence of symptoms present in any population.

Figure 2. Alluvial plots representing within-person changes in symptoms over time for a subset of individuals with complete data for all 3 recovery periods (n = 38). Y refers to the endorsement of the symptom at the respective time point, and N refers to absence. Endorsement is defined as presence of a symptom that either started or worsened at or after initial COVID-19 symptoms. Symptoms showing no variability among participants are not shown. Concentration problems refers to “trouble concentrating, trouble with your thinking, or trouble with your memory.” Vision problems refers to “trouble with vision, for example double vision, blurry vision, or other visual issues.” Abbreviation: COVID-19, coronavirus disease 2019.
Measuring self-reported magnitude of bother caused by symptoms is more informative than a simple present vs absent. Specifically, symptoms are inherently subjective, and what, for example, “presence of fatigue” means varies by person. Degree of bother, in contrast, provides better characterization and may, when focusing only on those with the highest level of bother, sharpen analyses seeking causes of symptoms. We also evaluated within-participant variability in symptoms over time and found some participants to have a waxing and waning course. This suggests that symptom course is not merely persistent or monotonically improving or worsening. Finally, quality of life is the ultimate integral of symptoms and, usually, what matters most to patients. We expect that quality-of-life measurements will become requisite in PASC research, and its importance means that electronic medical record–based ascertainment based on routine clinical care will typically not be sufficient.

Similar to findings about symptom clustering during acute SARS-CoV-2 infection [23], we found in a preliminary analysis that domains of symptoms clustered among those who reported symptoms during the postacute phase. While our sample size precluded an analysis of clustering of more granular symptoms or the identification of specific organ system–based phenotypes, we found that participants either tended to report many symptom domains (particularly fatigue, cardiopulmonary symptoms, and gastrointestinal symptoms) or just a few. This finding provides further support to the anecdotal observation that some patients are experiencing an extensive magnitude of symptom burden. Despite the limitations of our

| Table 3. Responses Regarding Symptoms of Anxiety, Depression, and Post-traumatic Stress at 16 and 32 Weeks Following Onset of COVID-19 Among Participants Enrolled in a Study of Postacute Sequelae of SARS-CoV-2 Infection |
|-----------------------------------|-----------------------------------|
| Mental Health Symptoms and Severity | Week 16 | Week 32 |
|                                    | (n = 119), % No. (%) | (n = 65), % No. (%) |
| Symptoms of anxiety (GAD-7 total score) |                                    |                      |
| Minimal (0–4)                       | 68 (44) | 33 (51) |
| Mild (5–9)                          | 86 (56) | 32 (49) |
| Moderate (10–14)                    | 0 (0)   | 0 (0)   |
| Severe (15–21)                      | 0 (0)   | 0 (0)   |
| Symptoms of depression (PHQ-8 total score) |                                    |                      |
| None (0–4)                          | 70 (54) | 39 (54) |
| Mild (5–9)                          | 19 (17) | 12 (20) |
| Moderate (10–14)                    | 13 (12) | 5 (8.0)|
| Moderately severe (15–19)           | 4 (3.5) | 3 (5.0)|
| Severe (20–24)                      | 4 (3.5) | 2 (3.0)|
| Symptoms of post-traumatic stress disorder (PCL-5 total score) |                      |                      |
| Score ≥10                           | 6 (6.0) | 7 (11) |

Abbreviations: COVID-19, coronavirus disease 2019; GAD-7, General Anxiety Disorder–7; PCL-5, Post-traumatic Stress Disorder Checklist; PHQ-8, patient health questionnaire-8; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

aTwenty-four responses at week 16 and 3 responses at week 32 are not expected due to differences in form versions used at the time of participant visit.

bMissing and nonresponse. GAD-7: 2 missing at week 16; PHQ-8: 3 responses missing at week 16, 5 missing at week 32; PCL-5: 8 missing at week 16, 1 missing at week 32.

cFour-item version of Post-Traumatic Stress Disorder Checklist 5; cutoff of 10 has 76% sensitivity and 52% specificity for meeting the diagnostic criteria for post-traumatic stress disorder.

| Table 4. Proportion of Participants Endorsing Presence of at Least 1 Symptom in the Symptom Domain, According to Cluster Status |
|-----------------------------------|-----------------------------------|
| Symptom Domain | Specific Symptoms in Domain | Cluster 1 | Cluster 2 |
| | | (n = 40), % (95% CI) | (n = 42), % (95% CI) |
| Fatigue | Fatigue | 90 (75–97) | 0 (0–10) |
| Upper respiratory | Runny nose and sore throat | 20 (10–36) | 21 (11–37) |
| Cardiopulmonary | Cough, chest pain, palpitation, and shortness of breath | 80 (64–90) | 31 (18–47) |
| Gastrointestinal | Abdominal pain, diarrhea, loss of appetite, and nausea | 52 (36–68) | 12 (4–26) |
| Musculoskeletal | Back pain, myalgia, and pain in the arms, legs, and joints | 40 (25–57) | 14 (6–29) |
| Neurologic | Anosmia, difficulty with concentration or memory, dizziness, dyageusia, headache, numbness, trouble with balance, and trouble with vision | 92 (79–98) | 69 (53–82) |
| Sleep | Trouble with sleep | 42 (27–59) | 26 (14–42) |

aClusters (or groups) derived from model-based clustering using the method of Marbac and Sedki [21]. Average silhouette score was 0.22; cluster-specific silhouette scores were 0.39 and 0.05 for Clusters 1 and 2, respectively.

bProportion (95% CI) endorsing at least 1 symptom in the symptom domain.
sample size, we believe that this is a first step in defining different subphenotypes of PASC, which is important not only for a comprehensive clinical description of the disorder but also for investigation of pathogenesis. That is, PASC may represent several different pathophysiologic conditions. Greater specificity in outcome classification using detailed measurements as outlined here will greatly increase the efficiency and accuracy of translational research that seeks to determine biochemical causes of the various subphenotypes [24]. As a practical example, our cluster analysis supports a strategy of grouping individuals based on the number of reported symptoms for pathophysiologic studies, at least until larger data sets can be used to identify more granular phenotypic clusters.

There are multiple mechanisms that might contribute to PASC. While SARS-CoV-2 infection definitionally initiates the pathogenesis of PASC, it is unclear whether viral antigen persists beyond the acute period, either in the form of persistent virus replication [25] or persistence of noninfectious genetic material or protein in the tissues [26]. Regardless of whether the virus persists, several mechanisms that are active in the recovery phase could explain PASC. First, systemic immune activation with alterations in B- and T-cell phenotypes and elevations in plasma cytokines and inflammatory markers could underlie at least some postacute sequelae [27–29]. Second, even in the absence of systemic inflammation, local tissue inflammation or ongoing immune cell infiltration into the tissues could result in tissue injury and remodeling, which could drive PASC through processes like microbial translocation in the gut [30] or tissue fibrosis in the heart or lungs [31, 32]. Third, multiple studies, including autopsy studies, have demonstrated endotheliitis and microvascular thrombosis in acute COVID-19, with neutrophil extracellular traps as one contributing mechanism [33–38]; in addition to explaining severe disease, ongoing microvascular dysfunction may contribute to the pathobiology of PASC. Fourth, autoreactive immunity may be a significant contributor, as immunoglobulin G autoantibodies are highly prevalent in

Table 5. Responses Regarding Quality of Life Before COVID-19, at the Self-Described Worst Point of COVID-19, and at Weeks 16 and 32 Following Onset of COVID-19 Among Participants Enrolled in a Study of Postacute Sequelae of SARS-CoV-2 Infection

| Quality of Life Domain | Response | Before Illness | Worst Point | Week 16 | Week 32 |
|-----------------------|----------|---------------|-------------|---------|---------|
| Mobility              | “Which of the following best describes your ability to walk about?” | No problems, % | 91 (n = 92) | 39 (n = 179) | 85 (n = 117) | 77 (n = 66) |
|                       |          | Slight problems, % | 6.0 | 10 (n = 92) | 9.0 (n = 179) | 11 (n = 117) | 8.0 (n = 66) |
|                       |          | Moderate problems, % | 2.0 | 29 (n = 92) | 4.0 (n = 179) | 8.0 (n = 117) | 8.0 (n = 66) |
|                       |          | Severe problems, % | 0 | 4.0 (n = 92) | 1.0 (n = 179) | 4.0 (n = 117) | 4.0 (n = 66) |
|                       |          | Unable to walk, % | 1.0 | 18 (n = 92) | 0.0 (n = 179) | 0.0 (n = 117) | 0.0 (n = 66) |
| Self-care             | “Which of the following describes your ability to wash and dress yourself?” | No problems, % | 95 (n = 92) | 60 (n = 179) | 96 (n = 117) | 90 (n = 66) |
|                       |          | Slight problems, % | 1.0 | 6.5 (n = 92) | 1.0 (n = 179) | 6.0 (n = 117) | 6.0 (n = 66) |
|                       |          | Moderate problems, % | 4.0 | 17 (n = 92) | 2.0 (n = 179) | 4.0 (n = 117) | 4.0 (n = 66) |
|                       |          | Severe problems, % | 0 | 15 (n = 92) | 1.0 (n = 179) | 0.0 (n = 117) | 0.0 (n = 66) |
|                       |          | Unable to wash or dress, % | 0 | 15 (n = 92) | 0 (n = 179) | 0 (n = 117) | 0 (n = 66) |
| Usual activities      | “Which of the following describes your ability to perform your usual activities?” | No problems, % | 95 (n = 92) | 31 (n = 179) | 81 (n = 117) | 77 (n = 66) |
|                       |          | Slight problems, % | 2.0 | 11 (n = 92) | 11 (n = 179) | 14 (n = 117) | 14 (n = 66) |
|                       |          | Moderate problems, % | 1.0 | 23 (n = 92) | 6.0 (n = 179) | 6.0 (n = 117) | 6.0 (n = 66) |
|                       |          | Severe problems, % | 2.0 | 7.0 (n = 92) | 2.0 (n = 179) | 5.0 (n = 117) | 5.0 (n = 66) |
|                       |          | Unable to do usual activities, % | 0 | 28 (n = 92) | 0 (n = 179) | 3.0 (n = 117) | 3.0 (n = 66) |
| Pain/discomfort*      | “Which of the following describes how much pain or discomfort you felt?” | No pain or discomfort, % | 70 (n = 92) | 27 (n = 179) | 65 (n = 117) | 52 (n = 66) |
|                       |          | Slight pain or discomfort, % | 20 | 13 (n = 92) | 14 (n = 179) | 26 (n = 117) | 26 (n = 66) |
|                       |          | Moderate pain or discomfort, % | 70 | 26 (n = 92) | 17 (n = 179) | 15 (n = 117) | 15 (n = 66) |
|                       |          | Severe pain or discomfort, % | 3.0 | 24 (n = 92) | 3.0 (n = 179) | 2.0 (n = 117) | 2.0 (n = 66) |
|                       |          | Extreme pain or discomfort, % | 0 | 10 (n = 92) | 1.0 (n = 179) | 5.0 (n = 117) | 5.0 (n = 66) |
|                       |          | Unable to wash or dress, % | 0 | 15 (n = 92) | 0 (n = 179) | 0 (n = 117) | 0 (n = 66) |
| Anxiety/depression*   | “Which of the following describes how anxious or depressed you felt?” | No anxiety or depression, % | 51 (n = 92) | 18 (n = 179) | 48 (n = 117) | 43 (n = 66) |
|                       |          | Slight anxiety or depression, % | 27 | 23 (n = 92) | 31 (n = 179) | 32 (n = 117) | 32 (n = 66) |
|                       |          | Moderate anxiety or depression, % | 17 | 24 (n = 92) | 15 (n = 179) | 14 (n = 117) | 14 (n = 66) |
|                       |          | Severe anxiety or depression, % | 2.0 | 17 (n = 92) | 4.0 (n = 179) | 6.0 (n = 117) | 6.0 (n = 66) |
|                       |          | Extreme anxiety or depression, % | 3.0 | 18 (n = 92) | 2.0 (n = 179) | 5.0 (n = 117) | 5.0 (n = 66) |

Visual analogue scale

“On a scale of 0 to 100, we would like to know how good or bad your health was…”

|                                                                 | Before Illness | Worst Point | Week 16 | Week 32 |
|-----------------------------------------------------------------|---------------|-------------|---------|---------|
|                                                                 | (n = 92)      | (n = 179)   | (n = 117)| (n = 66) |
| “On a scale of 0 to 100, we would like to know how good or bad your health was…” | 85 (n = 92) | 50 (n = 179) | 80 (n = 117) | 80 (n = 66) |

Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

*Not administered due to differences in form versions used at the time of participant visit: pain/discomfort: 22 from week 16 and 1 from week 32; anxiety/depression: 29 from week 16 and 1 from week 32.
in acute infection, including those associated with clinical disease entities similar to PASC [33, 39–42]. Importantly, some mechanisms may contribute to certain organ-specific morbidity, whereas others might cause other PASC phenotypes.

Our approach has several potential limitations that we believe will be of interest to investigators seeking to study PASC. One concern is the retrospective nature of the questioning about the acute phase of illness. It is our experience that participants who received formal RNA-confirmed diagnoses of SARS-CoV-2 infection claim no difficulty in remembering what symptoms they felt during the acute period. We believe this is the case because the sociocultural context associated with SARS-CoV-2 makes it different from other common infections (eg, influenza or rhinovirus). We concede, however, that recall may be imperfect. Yet, if memory is faulty, it is not obvious that symptoms reported a few months in retrospect would be systematically over- or underestimated or that current symptom status would influence recall. Because many studies of PASC will face this same issue, the field would benefit from formal investigation of retrospective patient reports compared with clinical notes made at the time of diagnosis.

More importantly, the nature of our participant sampling process limits what we can infer about PASC. It is axiomatic that our predominantly self-referred study population might be enriched for persons experiencing persistent symptoms because they were seeking answers for this condition. This may overestimate the parameter that all patients, clinicians, and scientists wish to know, which is the prevalence (at, eg, 4 or 8 months) of persistent symptoms among all persons infected with SARS-CoV-2. Alternatively, but less likely, it may be that persons who are most severely affected may be so debilitated that they were unable to travel to our research site. Relatedly, losses during longitudinal follow-up also pose a threat to artifactual enrichment of the study population for those with persistent symptoms. While most of our participants who missed their 32-week window did ultimately return to the study, it remains possible that the presence or absence of persistent symptoms systematically influenced who was able to attend an on-time visit. Therefore, it will only be through population-based probability samples and high longitudinal retention that researchers can be confident that their study populations are representative of the relevant targets for descriptive research, such as the prevalence of various sequelae. For these reasons, we are not emphasizing absolute percentages of the symptoms in this report. Likewise, the percentage of study participants with persistent symptoms that others [43–45] calculate cannot be interpreted as meaningful population-level prevalence. More recent reports have studied more representative populations [46–48], but there are far too few to form a consensus on true prevalence. While our sampling approach precludes estimation of population-level prevalence of symptoms, it will support biologically oriented research on the causes of PASC, which has already begun [29, 45, 49–54].

In summary, we have established a cohort of participants enrolled in the postacute phase of SARS-CoV-2 infection and have described our approach to research-level characterization of PASC symptoms and quality of life. We found that a large array of physical and mental health symptoms are reported up to 8 months following COVID-19 onset, many patients report these symptoms to be at least somewhat bothersome, and some report these symptoms intermittently over time. In a preliminary evaluation of symptom clustering, we found at least 2 groups. Collectively, these findings suggest that PASC is not monolithic and that multiple subphenotypes may exist. The convenience nature of our sampling—like many other nascent cohorts of PASC—precludes estimation of the population-level prevalence of these persistent symptoms, but it will allow for analytic work to study the pathogenesis of PASC. Larger population-based samples will be needed for unbiased estimates of prevalence of symptoms and quality of life, robust inferences regarding symptom clustering, and comprehensive assessment of the socio-behavioral determinants of PASC.

Acknowledgments

We are grateful to the LIINC study participants and to the clinical staff who provided care to these individuals during their acute illness period and during their recovery. We acknowledge current and former LIINC clinical study team members Tamara Abualhsan, Andrea Alvarez, Melissa Buitrago, Heather Hargit, Marian Kerbleski, James Lombardo, Dylan Ryder, Ruth Diaz Sanchez, Cassandra Thanh, and Fatima Ticas; LIINC laboratory team members Joanna Donatelli, Jill Hakim, Nikita Iyer, Owen Janson, Christopher Nixon, Isaac Thomas, and Kerstinne Turcios; and medical student volunteers Isabella Autsch, T. Allen Barnett, and Chloe Cattle. We thank Elnaz Eilkhani for coordination with the Institutional Review Board. We are grateful to LIINC collaborators Fran Aweeka, Jessica Briggs, Felicia Chow, Amelia Deitchman, Meredith Greene, Joanna Hellmuth, Laurence Huang, Peter Hunt, Mandana Khalili, Sulgi Lee, Lynn Pulliam, Edda Santiago Rodriguez, Lekshmi Santhosh, Ma Somsouk, and Joshua Vasquez for their scientific advice and collaboration. We acknowledge the contributions of the UCSF Clinical and Translational Science Unit, Core Immunology Laboratory, and AIDS Specimen Bank, as well as support and advice from the Division of HIV, Infectious Diseases, and Global Medicine and ZSFG Infection Control Service, in particular Diane Havlir, Vivek Jain, Carina Marquez, Lisa Winston, and Annie Luetskemeyer.

Financial support. This work was supported by the National Institutes of Health (R01 AI141003, R01 AI1158013, T32 AI60530, T32 HL007731, T32 AI135037, K23 AI157875, K23 AI146268 and K23 AI135037); MIDAS Coordination Center (MIDASNI2020-5); Chan Zuckerberg Biohub Investigator Fund; and the UCSF Resource Allocation Program.

Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Author contributions. M.J.P., J.D.K., T.J.H., S.G.D., and J.N.M. designed the cohort, which was overseen by M.J.P., J.D.K., R.L.R., I.R.B., B.G., T.J.H., S.G.D., and J.N.M. M.J.P., J.D.K., S.L., M.C.D., R.H., H.M.S., S.G.D., and J.N.M. designed the study instruments with input from V.T., E.A.F., L.T., Y.H., and K.A.; E.O.M., K.A.A., and J.P.-R. assisted with Spanish translation. M.J.P., R.H., V.T., E.A.F., L.T., Y.H., M.J.W., M.I.A., L.H.N., M.D., S.E.M., and E.M.O. recruited participants and coordinated research visits. M.J.P., J.D.K., M.C.D., R.H., V.T., E.A.F., L.T., Y.H., M.I.A., L.H.N., and S.E.M. administered study questionnaires and collected clinical data. J.A.B., M.C.W., and M.D.R. collected biospecimens. S.L., S.A.G., M.C.D., S.M., M.D., E.O.M., K.A.A., M.D.R., J.T., P.R.R., H.M.S., V.W.M., P.K.E., K.C.D., J.A.M., and during their recovery. We acknowledge current and former LIINC clinical study team members Tamara Abualhsan, Andrea Alvarez, Melissa Buitrago, Heather Hargit, Marian Kerbleski, James Lombardo, Dylan Ryder, Ruth Diaz Sanchez, Cassandra Thanh, and Fatima Ticas; LIINC laboratory team members Joanna Donatelli, Jill Hakim, Nikita Iyer, Owen Janson, Christopher Nixon, Isaac Thomas, and Kerstinne Turcios; and medical student volunteers Isabella Autsch, T. Allen Barnett, and Chloe Cattle. We thank Elnaz Eilkhani for coordination with the Institutional Review Board. We are grateful to LIINC collaborators Fran Aweeka, Jessica Briggs, Felicia Chow, Amelia Deitchman, Meredith Greene, Joanna Hellmuth, Laurence Huang, Peter Hunt, Mandana Khalili, Sulgi Lee, Lynn Pulliam, Edda Santiago Rodriguez, Lekshmi Santhosh, Ma Somsouk, and Joshua Vasquez for their scientific advice and collaboration. We acknowledge the contributions of the UCSF Clinical and Translational Science Unit, Core Immunology Laboratory, and AIDS Specimen Bank, as well as support and advice from the Division of HIV, Infectious Diseases, and Global Medicine and ZSFG Infection Control Service, in particular Diane Havlir, Vivek Jain, Carina Marquez, Lisa Winston, and Annie Luetskemeyer.

Financial support. This work was supported by the National Institutes of Health (R01 AI141003, R01 AI1158013, T32 AI60530, T32 HL007731, T32 AI135037, K23 AI157875, K23 AI146268 and K23 AI135037); MIDAS Coordination Center (MIDASNI2020-5); Chan Zuckerberg Biohub Investigator Fund; and the UCSF Resource Allocation Program.

Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Author contributions. M.J.P., J.D.K., T.J.H., S.G.D., and J.N.M. designed the cohort, which was overseen by M.J.P., J.D.K., R.L.R., I.R.B., B.G., T.J.H., S.G.D., and J.N.M. M.J.P., J.D.K., S.L., M.C.D., R.H., H.M.S., S.G.D., and J.N.M. designed the study instruments with input from V.T., E.A.F., L.T., Y.H., and K.A.; E.O.M., K.A.A., and J.P.-R. assisted with Spanish translation. M.J.P., R.H., V.T., E.A.F., L.T., Y.H., M.J.W., M.I.A., L.H.N., M.D., S.E.M., and E.M.O. recruited participants and coordinated research visits. M.J.P., J.D.K., M.C.D., R.H., V.T., E.A.F., L.T., Y.H., M.I.A., L.H.N., and S.E.M. administered study questionnaires and collected clinical data. J.A.B., M.C.W., and M.D.R. collected biospecimens. S.L., S.A.G., M.C.D., S.M., M.D., E.O.M., K.A.A., M.D.R., J.T., P.R.R., H.M.S., V.W.M., P.K.E., K.C.D., J.A.M.,
References

1. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708–20.

2. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020; 382:2372–4.

3. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323:2052–9.

4. Harding L. “Weird as hell”: the Covid-19 patients who have symptoms for months. Guardian. 15 May 2020. Available at: http://www.theguardian.com/world/2020/may/15/weird-hell-professor-advent-calendar-covid-19-symptoms-paul-garner. Accessed 7 March 2021.

5. Chuck E, Edwards E. Doctors couldn’t help these COVID-19 patients with their endless symptoms. So they turned to one another. NBC News. 17 May 2020. Available at: https://www.nbcnews.com/health/health-news/doctors-couldnt-help-these-covid-19-patients-their-endless-symptoms-ncala171616. Accessed 7 March 2021.

6. Horwitz J. Surviving Covid-19 may not feel like recovery for some. New York Times. 10 May 2020. Available at: https://www.nytimes.com/2020/05/10/world/europe/coronavirus-italy-recovery.html. Accessed 7 March 2021.

7. Yong E. COVID-19 can last for several months. The Atlantic. 4 June 2020. Available at: https://www.theatlantic.com/health/archive/2020/06/covid-19-coronavirus-longterm-symptoms-months/612679/. Accessed 7 March 2021.

8. Yong E. Long-haulers are reshaping COVID-19. The Atlantic. 18 August 2020. Available at: https://www.theatlantic.com/health/archive/2020/08/long-haulers-covid-19-recognition-support-groups-symptoms/615382/. Accessed 7 March 2021.

9. Davis HE, Assaf GS, McCorkell I, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021; 38:101019.

10. Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 2020; 7:e575–82.

11. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397:220–32.

12. Tenforde MW, Kim SS, Lindell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multisite health care systems network – United States, March-June 2020. MMWR Morb Mortal Wkly Rep 2020; 69:993–8.

13. Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002; 64:258–66.

14. Rabin R, Chiaro D. EQ-SD: a measure of health status from the EuroQol group. Ann Med 2003; 35:127–32.

15. Mathieu M, Mohammed S. Variable selection for model-based clustering using the integrated complete-data likelihood. Stat Comput 2015; 25:1049–63.

16. Marbac M, Sedki M. VarSelLCM: an R/C++ package for variable selection in model-based clustering of mixed-data with missing values. Bioinformatics 2019; 35:1255–7.

17. Matta J, Wierink E, Robineau O, et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic. JAMA Intern Med 2022; 182:19–25.

18. Sutradhar RR, Lee KA, Lochain MN, et al. Symptom clusters in COVID-19: a potential clinical prediction tool from the COVID symptom study app. Sci Adv. In press.

19. Webster AJ, Gatseskall K, Turnbull I, et al. Characterisation, identification, clustering, and classification of disease. Sci Rep 2021; 11:5405.

20. Zhang X, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China. January-March 2020: retrospective cohort study. BMJ 2020; 369:m1443.

21. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature 2021; 591:639–44.

22. Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020; 584:463–9.

23. Laing AG, Lorens A, del Molino del Barrio I, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med 2020; 26:1623–35.

24. Peluso MJ, Lu S, Tang AF, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. In press.

25. Giron LB, Dweep H, Yin X, et al. Severe COVID-19 is fueled by disrupted gut barrier integrity. bioRxiv 2020.11.23.20213209 [Preprint]. 16 November 2020. Available at: https://doi.org/10.1101/2020.11.13.20213209. Accessed 1 September 2021.

26. Puntmann VO, Carej MJ, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5:1265–73.

27. Huang L, Zhao P, Tang D, et al. Cardiac involvement in patients recovered from COVID-19 identified using magnetic resonance imaging. JACC Cardiovasc Imaging 2020; 13:2330–9.

28. Zuo Y, Estes SK, Ali RA, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med 2020; 12:eabd3876.

29. Gu SX, Tyagi T, Jain K, et al. Thrombocytopenia and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev 2021; 18:194–209.

30. Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 2020; 7:e575–82.

31. Rauch A, Dupont A, Gouty J, et al. Endotheliopathy is induced by plasma from critically ill patients and associated with organ failure in severe COVID-19. Circulation 2020; 142:1881–4.

32. Maccio U, Zinkernagel AS, Shambat SM, et al. SARS-CoV-2 leads to a small vessel endotheliitis in the heart. ElBioMedicine 2021; 63:103182.

33. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliopathies in COVID-19. Lancet 2020; 395:1417–8.

34. Chang SE, Feng A, Meng W, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun 2021; 12:5417.

35. Zhou Y, Han T, Chen J, et al. Clinical and autoimmune characteristics of severe COVID-19 in Crit Care Clin 2020; 36:1077–86.

36. Bhadelia N, Belkina AC, Olson A, et al. Distinct autoimmune antibody signatures between hospitalized acute COVID-19 patients, SARS-CoV-2 convalescent individuals, and unexposed pre-pandemic controls. bioRxiv 2021.01.21.21249176 [Preprint]. 16 November 2020. Available at: https://doi.org/10.1101/2021.01.21.21249176. Accessed 1 September 2021.

37. Ayoubkhani D. Prevalence of ongoing symptoms following coronavirus (COVID–19) infection in the UK - Office for National Statistics. 2021-07-16. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/2021-07-16. Accessed 7 April 2021.

38. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021; 594:259–64.
49. Peluso MJ, Deitchman AN, Torres L, et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep 2021; 36:109518.

50. Peluso MJ, Takahashi S, Hakim J, et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv 2021; 7:eabh3409.

51. Peluso MJ, Thomas JJ, Munter SE, Deeks SG, Henrich TJ. Lack of antinuclear antibodies in convalescent COVID-19 patients with persistent symptoms. Clin Infect Dis 2021; ciab890.

52. Peluso MJ, Munter SE, Lynch KL, et al. Discordant virus-specific antibody levels, antibody neutralization capacity, and T-cell responses following 3 doses of SARS-CoV-2 vaccination in a patient with connective tissue disease. Open Forum Infect Dis 2021; 8:XXX–XX.

53. Peluso MJ, Sans HM, Forman CA, et al. Plasma markers of neurologic injury and systemic inflammation in individuals with self-reported neurologic post-acute sequelae of SARS-CoV-2 infection (PASC). bioRxiv 2021.11.02.2126578 [Preprint]. 4 November 2021. Available at: https://doi.org/10.1101/2021.11.02.2126578. Accessed 15 November 2021.

54. Durstenfeld MS, Peluso MJ, Daniel Kelly J, et al. Role of antibodies, inflammatory markers, and echocardiographic findings in post-acute cardiopulmonary symptoms after SARS-CoV-2 infection. medRxiv 2021.11.24.21266834 [Preprint]. 26 November 2021. Available at: https://doi.org/10.1101/2021.11.24.21266834. Accessed 1 December 2021.